Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021030241 - IMMUNOMODULATORY COMPOUNDS

Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

[ EN ]

What is claimed is:

1. An anti-CD25 antibody comprising a Fab region that specifically binds to CD25 on T lymphocytes, and a mutated Fc region that does not bind to a Fc receptor.

2. The antibody of Claim 1, wherein the antibody does not block IL-2 binding to CD25.

3. The antibody of Claim 1, wherein the antibody increases regulatory T cell (Tregs) immunosuppressive function.

4. The antibody of Claim 1, wherein the antibody does not deplete regulatory T cells in vivo.

5. The antibody of Claim 1, wherein the antibody induces activation of integrins aίb2, a4b1, and a4b7 in CD4+ Foxp3+ T-regulatory cells.

6. The antibody of Claim 1, wherein the mutated Fc region is truncated as compared to a naturally occurring constant region.

7. The antibody of Claim 1, wherein the Fc region contains a substitution mutation as compared to a naturally occurring Fc region.

8. A method of treating an autoimmune disease or transplant rejection in a subject comprising administering to a subject in need an effective amount of the anti- CD25 antibody of any of claims 1-7.

9. The method of Claim 8, wherein the autoimmune disease is systemic lupus erythematosus, multiple sclerosis, rheumatoid arthritis, chronic inflammation, or inflammatory bowel disease.

10. The method of Claim 8, wherein the transplant rejection is due to pancreatic islet, heart, kidney, liver, lung, intestine, cornea, bone marrow, or connective tissue, transplantation or vascularized composite allografts.

11. A method of inhibiting an immune response in a subject comprising administering to a subject in need an effective amount of the anti-CD25 antibody of any of claims 1-7.

12. A method of stimulating regulatory T cells (Tregs) in a subject, comprising administering to a subject in need an effective amount of the anti-CD25 antibody of any of Claims 1-7.

13. A pharmaceutical composition comprising the antibody of any of Claims 1-7 and a pharmaceutically acceptable excipient.